糖皮质激素联合重组人促血小板生成素治疗重症ITP的疗效  

The effect of hormone combined with recombinant human thrombopoietin in treatment of severe ITP

作　　者：夏永寿 张涛[2] 梁蓉[2] 高广勋[2] 白庆咸[2] 杨岚[2] 

机构地区：[1]长安医院血液科,西安710016 [2]第四军医大学西京医院血液科

出　　处：《临床血液学杂志》2015年第6期954-956,共3页Journal of Clinical Hematology

摘　　要：目的:评价糖皮质激素联合重组人促血小板生成素(rhTPO)治疗重症原发免疫性血小板减少症(ITP)的疗效和安全性。方法:收集符合诊断标准的重症ITP患者39例,其中采用rhTPO治疗21例作为研究组(rhTPO组),采用丙种球蛋白治疗18例作为对照组(丙球组)。采用独立样本的非参数检验比较2组的临床疗效。结果:1rhTPO组和丙球组治疗有效率分别为95.2%和100%,2组间差异无统计学意义(P>0.05);2rhTPO组和丙球组血小板开始恢复时间分别为(4.44±0.88)d和(5.52±2.65)d,2组间差异无统计学意义(P>0.05);3治疗7d后,rhTPO组和丙球组血小板计数分别为(81.8±29.1)×109/L和(130.0±56.5)×109/L;而治疗14d后,血小板计数分别为(238.3±95.3)×109/L和(221.4±83.3)×109/L,2组间比较均差异无统计学意义(P>0.05)。结论:rhTPO联合地塞米松与丙种球蛋白联合地塞米松治疗重症ITP疗效相当,可作为重症ITP的一线治疗方法。Objective：To evaluate the efficacy and safety of glucocorticoid combined with recombinant human thrombopoietin（rhTPO）in treatment of severe newly diagnosed primary immune thrombocytopenia（ITP）.Method：A total of 39 patients were included according to the diagnostic standard,in which 21 cases were treated with rhTPO as the study group（rhTPO group）,18 cases were received gamma globulin treatment as the control group（immunoglobulin group）.Nonparametric test for independent samples was used to compare the clinical efficacy of two groups.Result：1The effective rates of rhTPO group and immunoglobulin group were 95.2%and 100%,there was no significant difference between two groups（P0.05）;2The start recovery time of platelet of rhTPO group and immunoglobulin group were（4.44±0.88）days and（5.52±2.65）days,there was no significant difference between them（P0.05）;3After treatment for 7days,platelet counts of rhTPO group and immunoglobulin group were（81.8±29.1）×109/L and（130.0±56.5）×109/L;After treatment for 14 days,platelet count were（238.3±95.3）×109/L and（221.4±83.3）×109/L,there were no significant differences between them（P〉0.05）.Conclusion：rhTPO combined with dexamethasone has the equivalent effect to gamma globulin combined with dexamethasone in the treatment of severe primary ITP,and it can be used as a treatment method for severe primary ITP.

关 键 词：重症原发免疫性血小板减少症 重组人促血小板生成素 糖皮质激素 丙种球蛋白 

分 类 号：R558.2[医药卫生—血液循环系统疾病]